CAR-T Meeting 2021 | Management of CAR-T related side effects
Ibrahim Yakoub-Agha
• 4 Feb 2021
Ibrahim Yakoub-Agha, MD, PhD, Lille University Hospital, Lille, France, briefly discusses the management of CAR-T related side effects, including cytokine-release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Close monitoring for CRS and ICANS is required throughout the treatment course. Additionally, pre-existing neurological comorbidities may be a risk factor for the development of ICANS. Therefore, the patients should be evaluated before CAR-T therapy to rule out pre-existing neurological abnormalities. This interview took place during the 3rd European CAR T-cell Meeting.
Disclosures
IYA received honorarium from Novartis. He is currently chair of the chronic malignancies working party of EBMT.
